N-[[(5-Methyl-3-phenylisoxazol-4-yl)- phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration

This publication has 12 references indexed in Scilit:

• The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
  Bioorganic & Medicinal Chemistry Letters, 1999
• Parenteral Ketorolac and Risk of Gastrointestinal and Operative Site Bleeding
  JAMA, 1996
• Ketorolac in Europe
  The Lancet, 1994
• Ketorolac doses reduced
  The Lancet, 1993
• The effect of immunomodulating drugs on adjuvant-induced arthritis in Lewis rats
  Inflammation Research, 1989
• Prodrug forms for the sulfonamide group. II. Water-soluble amino acid derivatives of N-methylsulfonamides as possible prodrugs
  International Journal of Pharmaceutics, 1988
• A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
  PAIN®, 1988
• Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamidines, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives
  International Journal of Pharmaceutics, 1987
• Book Reviews
  Journal of Medicinal Chemistry, 1986
• Synthesis, antiinflammatory and analgesic activity of 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids and related compounds
  Journal of Medicinal Chemistry, 1985